- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
High dose Anifrolumab Effective for Treatment of Lupus Nephritis
A two-year phase II TULIP-LN trial (NCT02547922) demonstrated the safety and efficacy of anifrolumab in treating active lupus nephritis, with the intensified dosing regimen showing particularly encouraging results. The findings were published in Lupus Science & Medicine.
The trial enrolled 147 patients who were randomly assigned to receive one of two anifrolumab dosing regimens or a placebo. Patients in the intensified regimen (IR) group received intravenous anifrolumab 900 mg for the first three doses, followed by 300 mg of anifrolumab every four weeks. The basic regimen (BR) group received 300 mg of anifrolumab, and the placebo group followed a similar dosing schedule. To continue into Year 2 of the trial, patients had to achieve at least a partial renal response and meet a glucocorticoid tapering target.
Out of the 101 patients who completed Year 1 of the study, 75 continued into Year 2, with 29 in the anifrolumab IR group, 23 in the BR group, and 23 in the placebo group. During Year 2, 72% of patients reported at least one adverse event (AE). Serious AEs were reported in 6.9% of the anifrolumab IR group, 8.7% of the BR group, and 8.7% of the placebo group. Three patients discontinued treatment due to an AE, and herpes zoster was reported in two patients.
Importantly, no COVID-19 cases were reported despite the trial overlapping with the start of the pandemic. More patients in the anifrolumab IR group achieved a complete renal response at Week 104 compared to those on BR or placebo (27.3% vs. 18.6% and 17.8%, respectively) while simultaneously sustaining glucocorticoid tapering (25.0% in the IR group, 18.6% in the BR group, and 17.8% in the placebo group). Additionally, estimated glomerular filtration rate improvements were numerically larger in both anifrolumab groups compared to the placebo group.
The results suggest that anifrolumab, particularly when administered using an intensified dosing regimen, exhibits a promising safety profile and improved efficacy in treating active proliferative LN. These findings provide a strong foundation for further investigations and may offer new hope for patients with this challenging autoimmune disease.
Reference:
Jayne, D., Rovin, B., Mysler, E., Furie, R., Houssiau, F., Trasieva, T., Knagenhjelm, J., Schwetje, E., Tang, W., Tummala, R., & Lindholm, C. (2023). Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. In Lupus Science & Medicine (Vol. 10, Issue 2, p. e000910). BMJ. https://doi.org/10.1136/lupus-2023-000910
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751